Vor Biopharma Inc. (VOR) NASDAQ
$1.67 (0.07) (-4.02%)
Market Cap: $118.70M
As of 04/25/24 11:10 AM EDT. Market open.
Vor Biopharma Inc. (VOR)
NASDAQ
$1.67
(0.07) (-4.02%)
Market Cap: $118.70M
As of 04/25/24 11:10 AM EDT. Market open.
Add to Portfolio
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
159
Address
.
PRICE CHART FOR VOR BIOPHARMA INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.68
Previous Close
$1.74
Days Range
$1.73 - $1.86
52 week range
$1.62 - $5.70
Volume
52,286
Avg. Volume (30 days)
293,975
Market Cap
$118.70M
Dividend Yield
-
P/E
-
Shares Outstanding
68,215,771
Open
$1.68
Previous Close
$1.74
Days Range
$1.73 - $1.86
52 week range
$1.62 - $5.70
Volume
52,286
Avg. Volume (30 days)
293,975
Market Cap
$118.70M
Dividend Yield
-
P/E
-
Shares Outstanding
68,215,771
FINANCIAL STATEMENTS FOR VOR BIOPHARMA INC
LOADING...
INSIDER TRANSACTIONS FOR VOR BIOPHARMA INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Jorgensen Nathan D. | CHIEF FINANCIAL OFFICER | Mar 01, 2024 | Option Exercise | $2.27 | 6,310 | 14,324 | 191,154 | Mar 05, 2024, 04:15 PM |
Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | Mar 01, 2024 | Option Exercise | $2.27 | 5,576 | 12,658 | 181,093 | Mar 05, 2024, 04:15 PM |
ANG ROBERT | PRESIDENT AND CEO | Mar 01, 2024 | Option Exercise | $2.27 | 12,657 | 28,731 | 815,480 | Mar 05, 2024, 04:15 PM |
Attar Eyal C. | CHIEF MEDICAL OFFICER | Feb 06, 2024 | Option Exercise | $2.32 | 1,180 | 2,738 | 112,853 | Feb 08, 2024, 05:10 PM |
ANG ROBERT | PRESIDENT AND CEO | Feb 06, 2024 | Option Exercise | $2.32 | 2,788 | 6,468 | 828,137 | Feb 08, 2024, 05:08 PM |
Jorgensen Nathan D. | CHIEF FINANCIAL OFFICER | Feb 06, 2024 | Option Exercise | $2.32 | 985 | 2,285 | 197,464 | Feb 08, 2024, 05:06 PM |
Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | Feb 06, 2024 | Option Exercise | $2.32 | 1,033 | 2,397 | 186,669 | Feb 08, 2024, 05:05 PM |
Chakraborty Tirtha | Chief Scientific Officer | Nov 06, 2023 | Option Exercise | $1.82 | 876 | 1,594 | 133,952 | Nov 08, 2023, 04:14 PM |
ANG ROBERT | President and CEO | Nov 06, 2023 | Option Exercise | $1.82 | 2,361 | 4,297 | 680,925 | Nov 08, 2023, 04:13 PM |
Jorgensen Nathan D. | Chief Financial Officer | Nov 06, 2023 | Option Exercise | $1.82 | 834 | 1,518 | 145,647 | Nov 08, 2023, 04:12 PM |
Attar Eyal C. | Chief Medical Officer | Nov 06, 2023 | Option Exercise | $1.82 | 999 | 1,818 | 51,533 | Nov 08, 2023, 04:10 PM |
Jorgensen Nathan D. | Chief Financial Officer | Sep 01, 2023 | Option Exercise | $2.67 | 6,310 | 16,848 | 146,481 | Sep 06, 2023, 04:31 PM |
Chakraborty Tirtha | Chief Scientific Officer | Sep 01, 2023 | Option Exercise | $2.67 | 5,576 | 14,888 | 134,828 | Sep 06, 2023, 04:29 PM |
ANG ROBERT | President and CEO | Sep 01, 2023 | Option Exercise | $2.67 | 12,657 | 33,794 | 683,286 | Sep 06, 2023, 04:28 PM |
Chakraborty Tirtha | Chief Scientific Officer | Aug 07, 2023 | Option Exercise | $2.67 | 875 | 2,336 | 140,404 | Aug 09, 2023, 04:38 PM |
Jorgensen Nathan D. | Chief Financial Officer | Aug 07, 2023 | Option Exercise | $2.67 | 834 | 2,227 | 152,791 | Aug 09, 2023, 04:37 PM |
Attar Eyal C. | Chief Medical Officer | Aug 07, 2023 | Option Exercise | $2.67 | 999 | 2,667 | 52,532 | Aug 09, 2023, 04:31 PM |
ANG ROBERT | President and CEO | Aug 07, 2023 | Option Exercise | $2.67 | 2,361 | 6,304 | 695,943 | Aug 09, 2023, 04:29 PM |
ANG ROBERT | President and CEO | May 08, 2023 | Option Exercise | $4.14 | 2,361 | 9,775 | 698,304 | May 10, 2023, 04:19 PM |
Chakraborty Tirtha | Chief Scientific Officer | May 08, 2023 | Option Exercise | $4.14 | 875 | 3,622 | 141,279 | May 10, 2023, 04:18 PM |
Jorgensen Nathan D. | Chief Financial Officer | May 08, 2023 | Option Exercise | $4.14 | 834 | 3,453 | 153,625 | May 10, 2023, 04:16 PM |
Attar Eyal C. | Chief Medical Officer | May 08, 2023 | Option Exercise | $4.14 | 969 | 4,012 | 53,531 | May 10, 2023, 04:14 PM |
ANG ROBERT | President and CEO | Mar 01, 2023 | Option Exercise | $5.51 | 12,657 | 69,740 | 700,665 | Mar 02, 2023, 06:39 PM |
Chakraborty Tirtha | Chief Scientific Officer | Mar 01, 2023 | Option Exercise | $5.51 | 5,576 | 30,724 | 142,154 | Mar 02, 2023, 06:37 PM |
Jorgensen Nathan D. | Chief Financial Officer | Mar 01, 2023 | Option Exercise | $5.51 | 6,310 | 34,768 | 154,459 | Mar 02, 2023, 06:35 PM |
Jorgensen Nathan D. | Chief Financial Officer | Mar 01, 2023 | Option Exercise | $5.51 | 6,310 | 34,768 | 154,459 | Mar 02, 2023, 06:35 PM |
RA CAPITAL MANAGEMENT, L.P. | Director | Dec 09, 2022 | Option Exercise | $4.30 | 11,627,907 | 50,000,002 | 20,923,554 | Dec 09, 2022, 04:32 PM |
5AM Ventures VI, L.P. | 10% Owner | Nov 16, 2021 | Sale | $15.30 | 330,706 | 5,059,802 | 4,595,089 | Nov 18, 2021, 08:14 PM |
PARMAR KUSH | Director | Nov 16, 2021 | Sale | $15.30 | 330,706 | 5,059,802 | 4,595,089 | Nov 18, 2021, 08:10 PM |
Chakraborty Tirtha | Chief Scientific Officer | Aug 17, 2021 | Option Exercise | $1.36 | 17,446 | 23,727 | 20,980 | Aug 19, 2021, 04:02 PM |
RA CAPITAL MANAGEMENT, L.P. | Director | Feb 09, 2021 | Buy | $18.00 | 2,979,566 | 53,632,188 | 8,297,265 | Feb 09, 2021, 06:25 PM |
5AM Ventures VI, L.P. | 10% Owner | Feb 09, 2021 | Buy | $18.00 | 555,555 | 9,999,990 | 4,833,959 | Feb 09, 2021, 06:03 PM |
PARMAR KUSH | Director | Feb 09, 2021 | Buy | $18.00 | 555,555 | 9,999,990 | 4,833,959 | Feb 09, 2021, 05:15 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
Jorgensen Nathan D. | CHIEF FINANCIAL OFFICER | 03/01/2024 | 14,324 |
Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | 03/01/2024 | 12,658 |
ANG ROBERT | PRESIDENT AND CEO | 03/01/2024 | 28,731 |
Attar Eyal C. | CHIEF MEDICAL OFFICER | 02/06/2024 | 2,738 |
ANG ROBERT | PRESIDENT AND CEO | 02/06/2024 | 6,468 |
Jorgensen Nathan D. | CHIEF FINANCIAL OFFICER | 02/06/2024 | 2,285 |
Chakraborty Tirtha | CHIEF SCIENTIFIC OFFICER | 02/06/2024 | 2,397 |
Chakraborty Tirtha | Chief Scientific Officer | 11/06/2023 | 1,594 |
ANG ROBERT | President and CEO | 11/06/2023 | 4,297 |
Jorgensen Nathan D. | Chief Financial Officer | 11/06/2023 | 1,518 |
Attar Eyal C. | Chief Medical Officer | 11/06/2023 | 1,818 |
Jorgensen Nathan D. | Chief Financial Officer | 09/01/2023 | 16,848 |
Chakraborty Tirtha | Chief Scientific Officer | 09/01/2023 | 14,888 |
ANG ROBERT | President and CEO | 09/01/2023 | 33,794 |
Chakraborty Tirtha | Chief Scientific Officer | 08/07/2023 | 2,336 |
Jorgensen Nathan D. | Chief Financial Officer | 08/07/2023 | 2,227 |
Attar Eyal C. | Chief Medical Officer | 08/07/2023 | 2,667 |
ANG ROBERT | President and CEO | 08/07/2023 | 6,304 |
ANG ROBERT | President and CEO | 05/08/2023 | 9,775 |
Chakraborty Tirtha | Chief Scientific Officer | 05/08/2023 | 3,622 |
Jorgensen Nathan D. | Chief Financial Officer | 05/08/2023 | 3,453 |
Attar Eyal C. | Chief Medical Officer | 05/08/2023 | 4,012 |
ANG ROBERT | President and CEO | 03/01/2023 | 69,740 |
Chakraborty Tirtha | Chief Scientific Officer | 03/01/2023 | 30,724 |
Jorgensen Nathan D. | Chief Financial Officer | 03/01/2023 | 34,768 |
Jorgensen Nathan D. | Chief Financial Officer | 03/01/2023 | 34,768 |
RA CAPITAL MANAGEMENT, L.P. | Director | 12/09/2022 | 50,000,002 |
5AM Ventures VI, L.P. | 10% Owner | 11/16/2021 | 5,059,802 |
PARMAR KUSH | Director | 11/16/2021 | 5,059,802 |
Chakraborty Tirtha | Chief Scientific Officer | 08/17/2021 | 23,727 |
RA CAPITAL MANAGEMENT, L.P. | Director | 02/09/2021 | 53,632,188 |
5AM Ventures VI, L.P. | 10% Owner | 02/09/2021 | 9,999,990 |
PARMAR KUSH | Director | 02/09/2021 | 9,999,990 |
Load More Insider Transactions
FUNDS WITH A POSITION IN VOR BIOPHARMA INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | 22,748,880 | 0.8% | No change | Other |
BLACKROCK INC. | 2,251,411 | 0.00013% | 6.86% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 794,063 | 0.00019% | 4.99% | Other |
RENAISSANCE TECHNOLOGIES LLC | 51,600 | 0.00018% | 41.37% | Other |
CHANGE IN SHARES OUTSTANDING FOR VOR BIOPHARMA INC
STOCK BUYBACKS FOR VOR BIOPHARMA INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.35%
1Q
06/30/2023
1.21%
2Q
03/31/2023
2.39%
3Q
12/31/2022
49.25%
4Q
09/30/2022
78.50%
5Q
06/30/2022
81.23%
6Q
03/31/2022
81.93%
7Q
12/31/2021
80.78%
8Q
09/30/2021
83.70%
9Q
06/30/2021
84.15%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR VOR BIOPHARMA INC
LOADING...